Roots Analysis has done a detailed study on Novel Antibody Therapies Market covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- Presently, around 55 players across the globe are engaged in developing novel antibody therapies for the treatment of multiple disease indications; majority of large players are based in North America
- Currently, majority of the radioimmunoconjugates are in clinical stages of development; more than 50% of the microbial immunotoxin candidates are administrated intravenously
- Several big pharma players have undertaken a variety of initiatives for novel antibodies, ranging from proprietary product development to patent filing
- 550+ clinical trials related to novel antibody therapies have been registered till date; majority (44%) of these trials were / are being conducted across various clinical sites based in Europe
- Over the past few years, more than 570 articles related to novel antibody therapies have been published by several eminent authors in high-impact journals; more than 50% of the articles were published in 2021
- Since 2017, more than 4,600 patents have been granted / filed for various novel antibody therapies, demonstrating the rising interest and rapid pace of research in this field
- The growing interest in this field is evident from the rise in partnership activity form the year 2020; a major proportion of the deals were signed by companies based in North America
- With the rising demand for new therapeutic modalities with high efficacy, the novel antibody therapies market is likely to grow at a steady pace till 2035
- The opportunity associated with novel antibody therapies market is likely to be well distributed across various types of therapies, route of administration and key geographical regions
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
3.2.1.1. Mechanism of Action of ADEPT
3.2.1.2. Advantages of ADEPT
3.2.1.3. Disadvantages of ADEPT
3.2.2. TCR like Antibodies
3.2.2.1. Mechanism of Action of TCR like Antibodies
3.2.2.2. Advantages of TCR like Antibodies
3.2.2.3. Disadvantages of TCR like Antibodies
3.2.3. Radioisotope Immunoconjugates
3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
3.2.3.2. Advantages of Radioisotope Immunoconjugates
3.2.3.3. Disadvantages of Radioisotope Immunoconjugates
3.2.4. Immunotoxins
3.2.4.1. Mechanism of Action of Immunotoxins
3.2.4.2. Advantages of Immunotoxins
3.2.4.3. Disadvantages of Immunotoxins
3.2.5. Intracellular Antibody
3.2.5.1. Mechanism of Action of Intracellular Antibody
3.2.5.2. Advantages of Intracellular Antibody
3.2.5.3. Disadvantages of Intracellular Antibody
3.2.6. Immunocytokines
3.2.6.1. Mechanism of Action of Immunocytokines
3.2.6.2. Advantages of Immunocytokines
3.2.6.3. Disadvantages of Immunocytokines
3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives
- NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Mechanism of Action
4.2.3. Analysis by Type of Cytokine
4.2.4. Analysis by Status of Development and Type of Cytokine
4.2.5. Analysis by Type of Antigen / Format
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Mode of Administration
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication(s)
4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
4.3.1. Analysis by Status of Development
4.3.2. Analysis by Mechanism of Action
4.3.3. Analysis by Type of Toxin
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Mode of Administration
4.3.7. Analysis by Immunotoxin Target
4.3.8. Analysis by Special Drug Designation
4.3.9. Analysis by Route of Administration
4.3.10. Analysis by Target Disease Indication(s)
4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
4.4.1. Analysis by Status of Development
4.4.2. Analysis by Type of Radioisotopes
4.4.3. Analysis by Status of Development and Type of Radioisotopes
4.4.4. Analysis by Route of Administration
4.4.5. Analysis by Type of Therapy
4.4.6. Analysis by Dosing Frequency
4.4.7. Analysis by Mode of Administration
4.4.8. Analysis by Special Drug Designation
4.4.9. Analysis by Target Disease Indication(s)
4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies)
4.6. Novel Antibody Therapies: List of Developers
4.6.1. Analysis by Type of Player
4.6.2. Analysis by Company Size
4.6.3. Analysis by Year of Establishment
4.6.4. Analysis by Location of Headquarters (Region-wise)
4.6.5. Analysis by Location of Headquarters (Country-wise)
4.6.6. Analysis by Company Size and Region of Headquarters
4.6.7. Leading Players: Analysis by Number of Therapeutics
- COMPANY PROFILES
5.1. Actinium Pharmaceuticals
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. Molecular Templates
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Philogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Roche
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Seagen
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Sesen bio
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Telix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Y-mAbs Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
- CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Trial Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Disease Indication(s)
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Type of Treatment
6.2.13. Analysis by Type of Drug
6.2.14. Word Cloud Analysis: Emerging Focus Areas
6.2.15. Analysis by Top Indication(s) and Trial Phase
6.2.16. Analysis by Top Indication(s) and Leading Industry Players
6.2.17. Analysis by Trial Location
6.2.18. Analysis by Geography and Trial Status
- PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Analysis by Type of Article
7.2.4. Top Authors: Analysis by Number of Publications
7.2.5. Key Journals: Analysis by Number of Publications
7.2.6. Key Journals: Analysis by Impact Factor
7.2.7. Most Popular Publishers: Analysis by Number of Publications
7.2.8. Most Popular Copyright Holders: Analysis by Number of Publications
- PATENT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
8.2.1. Analysis by Patent Publication Year
8.2.2. Year-wise Trend of Granted Patents
8.2.3. Analysis by Type of Patent
8.2.4. Analysis by Granted Patents and Patent Applications
8.2.5. Analysis by Geography
8.2.6. Analysis by CPC Symbols
8.2.7. Analysis by Type of Applicant
8.2.8. Analysis by Patent Age
8.2.9. Word Cloud Analysis: Emerging Focus Areas
8.2.10. Leading Industry Players: Analysis by Number of Patents
8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
8.2.12. Leading Individual Assignees: Analysis by Number of Patents
8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
8.2.14. Patent Valuation: Analysis Methodology and Parameters
8.2.15. Patent Valuation: Analysis by Relative Valuation
- PARTNERSHIPS AND COLLABORATIONS
9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Year and Type of Partnership
9.1.4. Most Popular Drug: Analysis by Number of Partnerships
9.1.5. Analysis by Types of Novel Antibodies
9.1.6. Analysis by Target Disease Indication(s)
9.1.7. Analysis by Type of Partnership and Target Indication(s)
9.1.8. Analysis by Type of Partner
9.1.9. Most Active Players: Analysis by Number of Partnerships
9.1.10. Most Active Players: Analysis by Type of Partnership
9.1.11. Regional Analysis of Partnerships
9.1.12. Intercontinental and Intracontinental Agreements
- BIG PHARMA PLAYERS
10.1 Analysis Methodology and Key Parameters
10.2. Scoring Criteria for Key Parameters
10.3. List of Big Pharma Players Focused on Novel Antibody Therapies
10.3.1. Analysis by Supplier Strength
10.3.2. Analysis by Portfolio Strength
10.3.3. Analysis by Portfolio Diversity
10.3.4. Benchmarking: Spider Web Analysis
10.3.5. Benchmarking: Harvey Ball Analysis
10.3.6. Benchmarking: Wind Rose Chart
- MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
11.3.1. Adcetris (Seagen)
11.3.1.2. Sales Forecast
11.3.2. Elzonris (Menarini Group)
11.3.2.2. Sales Forecast
11.3.3. Pluvicto (Novartis)
11.3.3.2. Sales Forecast
11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
11.4.3 Novel Antibody Therapies Market for Radioisotope Immunoconjugates, 2023-2035
11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035
11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035
11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035
11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035
11.9. Product-wise Sales Forecast (Phase III Drugs)
11.9.1. Adcetris (Seagen)
11.9.1.1. Target Patient Population
11.9.1.2. Sales Forecast
11.9.1.3. Net Present Value
11.9.1.4. Value Creation Analysis
11.9.2. Fibromun (Philogen)
11.9.2.1. Target Patient Population
11.9.2.2. Sales Forecast
11.9.2.3. Net Present Value
11.9.2.4. Value Creation Analysis
11.9.3. Iomab-B (Actinium Pharmaceuticals)
11.9.3.1. Target Patient Population
11.9.3.2. Sales Forecast
11.9.3.3. Net Present Value
11.9.3.4. Value Creation Analysis
11.9.4. Nidlegy (Philogen)
11.9.4.1. Target Patient Population
11.9.4.2. Sales Forecast
11.9.4.3. Net Present Value
11.9.4.4. Value Creation Analysis
11.9.5. T-Guard (Xenikos)
11.9.5.1. Target Patient Population
11.9.5.2. Sales Forecast
11.9.5.3. Net Present Value
11.9.5.4. Value Creation Analysis
11.9.6. TLX 591 (Telix Pharmaceuticals)
11.9.6.1. Target Patient Population
11.9.6.2. Sales Forecast
11.9.6.3. Net Present Value
11.9.6.4. Value Creation Analysis
11.9.7. Vicinium (Sesen Bio)
11.9.7.1. Target Patient Population
11.9.7.2. Sales Forecast
11.9.7.3. Net Present Value
11.9.7.4. Value Creation Analysis
- APPENDIX 1: TABULATED DATA
- APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html
You may also be interested in the following titles:
Cell Therapy Manufacturing Market
You may also like to learn what our experts are sharing in Roots educational series:
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
